Skip to content

SARS-CoV-2 Safety Study for the Treatment of COVID-19

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06489860
Acronym
SARS-CoV-2
Enrollment
0
Registered
2024-07-08
Start date
2025-01-28
Completion date
2025-02-04
Last updated
2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Brief summary

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Detailed description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells. CHEMISTRY: SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives. Toxicology: SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology. SARS-CoV-2 is not placebo drug

Interventions

DRUGHIV

Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date

DRUGMalignant Neoplasms Safety Study for the Treatment of Neoplasms

Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.

Sponsors

DHA Coffee Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2 Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Intervention model description

SARS-CoV-2. Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2. Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g.

Eligibility

Sex/Gender
ALL
Age
1 Years to 130 Years
Healthy volunteers
Yes

Inclusion criteria

* SARS-CoV-2

Design outcomes

Primary

MeasureTime frameDescription
SARS-CoV-2From September to October, 20241. Parameters: Humidification, Unit: %, Result: 4.40, Test Method: ISO 7932: 2004. 2. Cadmium (Cd), mg/Kg, 0.1, CASE.TN.0018 (Ref. AOAC 999.11). 3. Hydrargyrum (Hg), mg/Kg, 0.01, CASE.TN.0141 (Ref . EPA Method 7473). 4. Plumbum (Pb), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017. 5. Cadmium (Cd), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. . 6. Arsen (As), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017. 7. Hydrargyrum (Hg), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. 8. Clostridium perfringents, CFU/g, \< 10, ISO 7937:2004. 9. Coliforms, CFU/g, \< 10, ISO 4832:2006 (\*). 10. Escherichia coli, CFU/g, \< 10, ISO 7937:2006. 11. Salmonella, /25g, Not detected, ISO 7937:2007. 12. Staphylococcus aureus, CFU/g, \< 10, ISO 7937:2008. 13. Total Yeasts molds, CFU/g, \< 10, ISO 7937:2009. 14. Total Aerobic Microbial, CFU/g, 1.0 x 100, ISO 7937:2010. 15. Vibrio parahaemolyticuc, /25g, Not detected, ISO 7937:2011. .

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026